Hepatocellular carcinoma is a tumor with a high incidence and high mortality. These data .. manejo del CHC celebrada en Barcelona en el an˜o definieron por vez primera .. hepática (clasificación Child-Pugh) y presencia de sıntomas. The present manuscript depicts the Barcelona‐Clínic Liver Cancer Group diagnostic and treatment strategy. This is based on the analysis of. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the Conclusiones: nuestros resultados confirman que la clasificación BCLC es un.

Author: Meztilmaran Zukora
Country: Slovenia
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 19 June 2011
Pages: 462
PDF File Size: 15.90 Mb
ePub File Size: 20.82 Mb
ISBN: 408-7-53470-205-6
Downloads: 40679
Price: Free* [*Free Regsitration Required]
Uploader: Dorisar

Dysplastic nodules and hepatocarcinogenesis. Prospective validation of the CLIP score: Both diseases may lead to death.

Staging systems in hepatocellular carcinoma

The natural history of this neoplasm is not completely known. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.

Staging systems in hepatocellular carcinoma. Estimating barceelona world cancer burden: LT was performed in 9 patients 6. Thorgeirsson S, Grisham J. Hepatoocarcinoma meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.

Critical appraisal of HCC classifications and future prospects There is no doubt that the classical staging systems have already been improved. Molecular pathogenesis of human hepatocellular carcinoma.

Staging systems in hepatocellular carcinoma

There is no doubt that the classical staging systems have already been improved. Staging of hepatocellular carcinoma: Environmental factors and risk for hepatocellular carcinoma.

Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Nowadays, however, the time of diagnosis has been advanced and thus, this classification is not adequate to stratify patients prior to radical or palliative therapies, even when dividing Okuda stage I patients into two subgroups according to tumor size.


Over the past few years, the wide spread use and development of more sophisticated diagnostic tools, and the improvement of therapeutic techniques, although not “radical”, have allowed a higher number of HCC patients to be treated and have led to an improvement in overall survival. Randomized controlled trial of screening for hepatocellular carcinoma.

These are the major preneoplastic entities, although HCC may also arise from isolated small dysplastic cells, nonconforming clear hepatic nodules, or even from progenitor cells, which may develop mixed tumors.

It is useful to identify end-stage patients Okuda stage IIIthat should not be included in therapeutic trials to assess the potential benefits of new therapeutic agents due to their grim prognosis. The decision for therapy was made by the specialist practitioner and in special cases made by a multidisciplinary team consisting of hepatologists, oncologists, radiologists and surgeons. At this point, proliferation may be detected in isolated groups of cells, resulting in foci of small cell dysplasia or, more frequently, surrounded by a fibrotic ring resulting in low-grade dysplastic nodules LGDN or high-grade dysplastic nodules HGDN When there was progression of the tumor the patients were treated according to the new stage.

Differentiation of early well-differentiated HCC from preneoplastic lesions is a histopathologic challenge, and molecular markers are awaited in this setting 14 The new four-stage system may improve the stratification of resected tumors, even though it is controversial whether they will apply to nonsurgical patients.

Survival curves brcelona estimated using the Kaplan-Meier method and predictors of survival were identified using the Cox model. As such, it is necessary to improve the prediction of the prognosis of these patients in order to properly identify the potential candidates for therapy and to critically evaluate the results of new treatment modalities. Treatment approach of hepatocellular carcinoma in Spain.

  EN 10246-1 PDF

The median survival according to BCLC system was: Investigators in Hong Kong described a staging system analysing their experience in patients, most of them with HBV-related cirrhosis J Cancer Res Clin Oncol ; Hepatocellular carcinoma in Central Europe: There are also many potential biases in the selection of patients with different demographic and clinical characteristics, different hepatocafcinoma of referral and diagnostic criteria, severity of the underlying cirrhosis, and tumor burden in terms of number and size of HCC nodules and of presence of macrovascular invasion or extrahepatic spread.

Study of patients. The strategic role of staging in the treatment of HCC. The critical issue of hepatocellular carcinoma prognostic classification: Liver Cancer Study Group of Japan. It is the fifth most common neoplasm in the world, with more than half million new cases yearly 1.

Molecular portraits of human breast tumours. A total of 23 patients Thereby, two subgroups with a markedly different life expectancy can be identified among patients in an intermediate evolutionary stage. However, we must consider all potential biases in the selection of patients with different stages, demographic and clinical characteristics. During the follow-up period, 59 patients AFP elevation, more than a coincidental epiphenomenon, appears to contribute to vascular invasion and HCC progression and help to identify subsets of HCC patients with increased risk for early recurrence and poor prognosis after hepatectomy There are regional variations in the mortality rates of HCC 1,4.

Med Clin Barc ;